// App-Quantinova.ai

: Single Centre UK Comparison of Biosimilar Rituximab (Truxima) with the Originator (MabThera) in Patients with Immune Mediated Thrombotic Thrombocytopenic Purpura

Researchers

Presenter

  • Matthew J. Stubbs

Principal Investigators

  • Ryan Low

  • Siobhan McGuckin

  • Rosalind Newton

  • John-Paul Westwood

  • Mari Thomas

  • Simon Cheesman

  • Marie Scully

Medical Centers

  • Department of Urology, King's College Hospital NHS Foundation Trust, London, United Kingdom

  • Haematology, University College London Hospitals NHS Foundation Trust (UCLH), London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Genetic Disorder

Disease

  • Thrombotic thrombocytopenic purpura

Biomarkers

  • Cluster of Differentiation 19

Drug/Treatment

  • Rituximab biosimilar

  • Rituximab

  • Rituximab-abbs

Outcome

  • N/A

Study Design

  • Cohort

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved